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Mesenchymal stem cells (MSCs) are multipotent adult stem
cells that have regenerative capability and exert paracrine
actions on damaged tissues. Since peritoneal fibrosis is a
serious complication of peritoneal dialysis, we tested whether
MSCs suppress this using a chlorhexidine gluconate model in
rats. Although MSCs isolated from green fluorescent protein–
positive rats were detected for only 3 days following their
injection, immunohistochemical staining showed that MSCs
suppressed the expression of mesenchymal cells, their effects
on the deposition of extracellular matrix proteins, and the
infiltration of macrophages for 14 days. Moreover, MSCs
reduced the functional impairment of the peritoneal membrane.
Cocultures of MSCs and human peritoneal mesothelial cells
using a Transwell system indicated that the beneficial effects
of MSCs on the glucose-induced upregulation of transforming
growth factor-b1(TGF-b1) and fibronectin mRNA expression
in the human cells were likely due to paracrine actions.
Preincubation in MSC-conditioned medium suppressed TGF-
b1-induced epithelial-to-mesenchymal transition, a-smooth
muscle actin, and the decrease in zonula occludens-1 in
cultured human peritoneal mesothelial cells. Although bone
morphogenic protein 7 was not detected, MSCs secreted
hepatocyte growth factor and a neutralizing antibody to this
inhibited TGF-b1 signaling. Thus, our findings imply that MSCs
ameliorate experimental peritoneal fibrosis by suppressing
inflammation and TGF-b1 signaling in a paracrine manner.
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Peritoneal dialysis (PD) has been used as a beneficial
treatment for end-stage kidney disease. However, peritoneal
fibrosis remains a serious complication of long-term PD that
leads to the failure of peritoneal function.1,2 Peritoneal fibrosis
arises in response to a variety of injurious factors, including
bioincompatible dialysate components, uremic toxins,
refractory or recurrent infectious peritonitis, and chronic
inflammation.3–5 The characteristic histological features of
the fibrotic sclerosing peritoneum are loss of peritoneal
mesothelial cells, abnormal proliferation of a-smooth muscle
actin (a-SMA)-positive myofibroblasts, marked accumulation
of collagen, and a progressive increase in the thickness of the
submesothelial compact zone.5,6
As the essential mechanism of peritoneal fibrosis, the
epithelial-to-mesenchymal transition (EMT) has been iden-
tified in cultured human peritoneal mesothelial cells
(HPMCs)7 and in PD patients.8 Many studies have
reported that transforming growth factor-b1 (TGF-b1) has
a pivotal role in the induction of EMT,7,9 typically
characterized by reduced cell–cell adhesion, loss of epithelial
polarity, and de novo expression of a-SMA and other
fibrogenic mediators.10,11 On binding to its receptors (types
I and II serine/threonine kinases), TGF-b1 signaling leads to
phosphorylation of receptor-regulated Smads (R-Smads)
such as Smad2 and Smad3. Subsequently, R-Smads form a
heteromultimer with Smad4, translocate to the nucleus, and
regulate transcription of target genes.12 The Smad proteins
are thought to have an important role in the process of
fibrosis. Various studies performed in vitro and in animal
models have suggested that drugs, peptides, and gene therapy
targeting fibrosis and/or angiogenesis could be useful for
treating peritoneal fibrosis,13–16 whereas clinically available
treatment for peritoneal fibrosis in PD patients remains
limited at present.
Mesenchymal stem cells (MSCs) are multipotent adult
stem cells that can be obtained from the bone marrow
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and many other tissues.17–19 MSCs have been used for the
regeneration of various tissues because these cells have the
capability to differentiate into a variety of lineages, including
bone, cartilage, cardiac myocytes, and neurons.20–23 In
addition to their regenerative capability, MSCs display
immunomodulatory and antifibrotic activity that could be
important in the response to injury.24 The antifibrotic effects
of cultured MSCs have been demonstrated in different
animal models.25,26 Although ex vivo-expanded MSCs have
been used in many basic studies and clinical trials, few
authors have assessed the potential of MSCs to inhibit
peritoneal fibrosis. Mesothelial cell transplantation has been
studied in animal models and PD patients,27,28 and this
approach may be one of the options for alleviating peritoneal
membrane dysfunction. Because infusion of autologous
MSCs is considered to be safe and has few adverse effects,
it seems to be promising for clinical use.
In this work, we initially examined whether intraperito-
neal infusion of MSCs could engraft and ameliorate
chlorhexidine gluconate (CG)-induced peritoneal fibrosis in
a rat model. To elucidate the paracrine effect of MSCs, we
cocultured glucose-stimulated HPMCs with human MSCs
using a Transwell system and investigated the expression of
TGF-b1 and fibronectin. Lastly, we investigated the effects of
MSC-conditioned medium (MSC-CM) on TGF-b1-induced
Smad2 activation and the EMT response of HPMCs.
Our findings demonstrated that MSCs were retained in
the peritoneum, inhibited inflammation, and ameliorated
peritoneal fibrosis, thereby reducing the functional impair-
ments of the peritoneal membrane. Moreover, MSCs
inhibited glucose-induced TGF-b1 production and amelio-
rated the TGF-b1-induced EMT by inhibition of TGF-b1
signaling in HPMCs by exerting paracrine actions, including
secretion of hepatocyte growth factor (HGF).
RESULTS
MSCs suppressed the accumulation of peritoneal cells and
the thickening induced by CG
Hematoxylin–eosin staining (Figure 1a) was used to assess
changes in cell density, and Masson’s trichrome staining
(Figure 1b) was used to analyze peritoneal thickening. We
found that injection of 2ml of 0.1% CG induced thickening
of the submesothelial compact zone, and that the thickness
and cellularity of this zone gradually increased until day 14.
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Figure 1 |Mesenchymal stem cells (MSCs) suppressed peritoneal cell density and thickening in chlorhexidine gluconate (CG)-injected
rats. (a, b) Representative light microscopic features of peritoneal tissues on days 7 and 14 (a: hematoxylin–eosin stain; b: Masson’s
trichrome stain, original magnification 200) in control rats, CG-injected rats treated with the vehicle, and CG-injected rats treated with MSCs.
(c, d) The thickness of the submesothelial compact zone increased along with its cellularity until day 14 in rats treated with the vehicle,
whereas cell density and thickening of the zone were suppressed in rats treated with MSCs. Bars show the compact zone area. *Po0.01 versus
control group, #Po0.05 versus CGþ vehicle group.
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On day 7, the thickness of the submesothelial compact zone
did not differ markedly between the rats treated with the
vehicle and the rats that had been treated with MSCs
(1107 cells) injected intraperitoneally 30min after CG
stimulation. In contrast, the cell density of the collagenous
compact zone was significantly suppressed in rats treated
with MSCs compared with rats given the vehicle. On day 14,
both peritoneal cell density and thickness were suppressed in
rats treated with MSCs compared with rats given the vehicle
(Figure 1c and d).
MSCs suppressed the expression of mesenchymal markers
and extracellular matrix proteins in rats with peritoneal
fibrosis
We examined the peritoneal expression of a-SMA and
fibroblast-specific protein-1 (FSP-1) as mesenchymal
markers. After injection of CG, a-SMA expression was found
in myofibroblasts that accumulated in the upper layer of the
submesothelial compact zone on days 7 and 14, as well as in
vascular smooth muscle cells (Figure 2a). Treatment with
MSCs significantly suppressed the extent of the a-SMA-
positive area on days 7 and 14 compared with rats receiving
the vehicle (Figure 2c). Figure 2b shows that FSP-1þ cells
also accumulated in the upper layer of the submesothelial
compact zone on days 7 and 14. Treatment with MSCs
significantly suppressed the number of FSP-1þ cells on days
7 and 14 compared with that in rats receiving the vehicle
(Figure 2d). Collagens I and III are extracellular matrix
proteins, and we showed that collagens I and III were
expressed in the submesothelial compact zone on day 7 and
showed an increase by day 14 (Figure 3a and b). Treatment
with MSCs reduced the area in which collagens I and III
accumulated on days 7 and 14 compared with the effect of
the vehicle alone (Figure 3c and d).
MSCs suppressed infiltration of monocytes/macrophages and
TGF-b1/Smad signaling
To evaluate monocyte/macrophage infiltration into the
peritoneum, we examined CD68 expression. We found an
accumulation of CD68þ cells in the submesothelial zone on
day 7 and a further increase on day 14 (Figure 4a). Treatment
with MSCs significantly inhibited the infiltration of CD68þ
cells on days 7 and 14 compared with that in rats receiving
the vehicle alone (Figure 4d). The majority of CD68þ cells
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Figure 2 |Mesenchymal stem cells (MSCs) suppressed a-smooth muscle actin (a-SMA) and fibroblast-specific protein-1 (FSP-1)
expressions in rats with peritoneal fibrosis. Immunohistochemical analyses of (a) a-SMA and (b) FSP-1 expression in peritoneal tissues on
days 7 and 14 (original magnification 200) in control rats, chlorhexidine gluconate (CG)-injected rats treated with the vehicle alone,
and CG-injected rats treated with MSCs. (c, d) Accumulation of a-SMAþ and FSP-1þ cells was observed on days 7 and 14 in CG-injected rats
treated with the vehicle, whereas the areas (percentage) of a-SMA expression and the number of FSP-1þ cells were significantly smaller
on both days 7 and 14 in CG-injected rats treated with MSCs. *Po0.01 versus control group, #Po0.05 versus CGþ vehicle group.
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showed immunoreactivity for TGF-b1 (Figure 4c, arrows),
demonstrating colocalization of CD68 and TGF-b1. The
number of cells double positive for CD68 and TGF-b1 in the
submesothelial zone increased until day 14 (Figure 4b).
Administration of MSCs significantly inhibited the infiltra-
tion of cells double positive for CD68 and TGF-b1 on days 7
and 14 compared with treatment with the vehicle alone
(Figure 4e). Moreover, immunoreactivity of phosphorylated
Smad2 (pSmad2) was seen in nuclei. pSmad2þ cells
increased in the submesothelial zone on day 7 and showed
a further increase on day 14 (Figure 5a). Treatment with
MSCs significantly inhibited the number of pSmad2þ cells
on days 7 and 14 compared with those in rats receiving the
vehicle alone (Figure 5b).
MSCs reduced the functional impairments of the peritoneal
membrane in rats with peritoneal fibrosis
A peritoneal equilibrium test was performed on day 14 to assess
the functional alteration of the peritoneal membrane. The
absorption rate of glucose from the dialysate and the transport
rate of blood urea nitrogen from the plasma were significantly
higher in CG-injected rats treated with the vehicle alone than
in control rats, whereas it was significantly improved in
CG-injected rats treated with MSCs (Figure 6a and b).
GFP-labeled MSCs showed temporary retention in the
peritoneum following stimulation by CG
To assess the fate of intraperitoneally injected MSCs, we
injected green fluorescent protein (GFP)-labeled MSCs after
CG stimulation. As a control, we injected GFPþ MSCs
without CG injection (vehicle injection alone). As a result,
GFPþ MSCs were observed in the parietal peritoneum,
omentum, and diaphragm of MSC-treated rats until day 3
(Figures 7a–c), but these cells were not detected on
day 7 or day 14. The number of GFPþ MSCs in the
parietal peritoneum was 7.39±2.06 cells/10 fields (100
magnification) on day3. In contrast, no GFPþ MSCs were
observed at any time in the parietal peritoneum of MSC-
treated rats without intraperitoneal injection of CG
(Figure 7d). We also could not detect GFPþ MSCs in other
tissues such as the spleen, liver, lungs, or kidneys in either
CG-stimulated rats or control rats at any time of assessment.
These results indicate that MSCs were retained in the affected
tissues for only a few days.
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Figure 3 |Mesenchymal stem cells (MSCs) suppressed collagen I and III expressions in rats with peritoneal fibrosis. Immunohisto-
chemical analyses of (a) collagen I and (b) collagen III expression in peritoneal tissues on days 7 and 14 (original magnification 200) in control
rats, chlorhexidine gluconate (CG)-injected rats treated with the vehicle alone, and CG-injected rats treated with MSCs. (c, d) The numbers
of collagen Iþ and IIIþ pixels were increased on days 7 and 14 in CG-injected rats treated with the vehicle, whereas the numbers of
collagen Iþ and IIIþ pixels were significantly smaller on days 7 and 14 in CG-injected rats treated with MSCs. *Po0.01 versus control
group, #Po0.05 versus CGþ vehicle group.
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Figure 4 |Mesenchymal stem cells (MSCs) suppressed monocyte/macrophage infiltration and transforming growth factor-b1 (TGF-b1)
expression in rats with peritoneal fibrosis. (a) Immunohistochemical analysis of CD68 expression in peritoneal tissues on days 7 and 14 in
control rats, chlorhexidine gluconate (CG)-injected rats treated with vehicle alone, and CG-injected rats treated with MSCs. (b) Two-color
immunohistochemical analysis of CD68 (brown) and TGF-b1 (blue–gray) expression in peritoneal tissues on day 14 in CG-injected rats
treated with the vehicle alone and CG-injected rats treated with MSCs. (c) The majority of CD68þ cells showed immunoreactivity for TGF-b1
(arrows). (d) The number of CD68þ cells increased until day 14 in CG-injected rats treated with the vehicle alone, whereas it was significantly
smaller on days 7 and 14 in CG-injected rats treated with MSCs. (e) The number of cells double positive for CD68 and TGF-b1 increased until
day 14 in CG-injected rats treated with vehicle alone, whereas it was significantly smaller on days 7 and 14 in CG-injected rats treated
with MSCs. *Po0.01 versus control group, #Po0.05 versus CGþ vehicle group (original magnification: a and c 400; b 200).
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Figure 5 |Mesenchymal stem cells (MSCs) suppressed phosphorylated Smad2 (pSmad2) expression in rats with peritoneal fibrosis.
(a) Immunohistochemical analysis of pSmad2 expression in peritoneal tissues on days 7 and 14 (original magnification 200) in control rats,
chlorhexidine gluconate (CG)-injected rats treated with vehicle alone, and CG-injected rats treated with MSCs. (b) The number of pSmad2þ
cells increased until day 14 in CG-injected rats treated with vehicle alone, whereas it was significantly smaller on days 7 and 14 in CG-injected
rats treated with MSCs. *Po0.01 versus control group, #Po0.05 versus CGþ vehicle group.
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Human MSCs suppressed glucose-induced TGF-b1 and
fibronectin expression in HPMCs
To investigate whether the effect of human MSCs on
glucose-induced TGF-b1 and fibronectin gene expression in
HPMCs required cell–cell contact, HPMCs were treated with
4% D-glucose for 12 h and then were cocultured with the
vehicle alone or with human MSCs using a Transwell system
for 24 h. Glucose treatment significantly induced the expres-
sion of TGF-b1 and fibronectin mRNAs compared with that
in control cells, whereas coculture of HPMCs with human
MSCs resulted in a significant reduction of TGF-b1 and
fibronectin mRNA expression compared with the levels in
vehicle-treated cells (Figure 8a and b). These results suggest
that MSCs acted to suppress the fibroproliferative response of
HPMCs in a paracrine manner.
MSC-CM inhibited TGF-b1-induced phosphorylation of Smad2
and counteracted TGF-b1-induced EMT of HPMCs
TGF-b1 is the most potent growth factor that can induce
EMT in various types of cells.29 To investigate whether MSCs
suppressed fibrotic change through paracrine effects, we
prepared MSC-CM from 2-day cultures of MSCs and
examined its effects on TGF-b1-induced EMT of HPMCs.
HPMCs were incubated with MSC-CM for 12 h and then
stimulated with TGF-b1 at 2.5 ng/ml. Morphologic changes
of cultured HPMCs 48 h after the stimulation are shown in
Figure 9a–d. There were no significant changes in the
characteristic cobblestone-like appearance of control HPMCs
and HPMCs incubated with MSC-CM without TGF-b1
stimulation. Fibroblastoid change was observed following
TGF-b1 stimulation, whereas the change was milder in
HPMCs incubated with MSC-CM than that in HPMCs
incubated with normal medium. Western blot analysis shows
that MSC-CM inhibited TGF-b1-induced phosphorylation of
Smad2 in HPMCs (Figure 9e). TGF-b1 treatment for 48 h
increased a-SMA (mesenchymal marker) protein expression
and decreased zonula occludens-1 (epithelial marker) protein
expression. MSC-CM attenuated these TGF-b1-induced
EMT responses (Figure 9f and g).
MSC secreted HGF and inhibited TGF-b1 signaling in HPMCs
It is well recognized that HGF and bone morphogenic protein
7 (BMP-7) have inhibitory effects on TGF-b1 signaling
and suppress EMT.30–32 We cultured HPMCs and human
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Figure 7 | Green fluorescent protein (GFP)-positive mesenchymal
stem cells (MSCs) were briefly retained in the peritoneum after
stimulation by chlorhexidine gluconate (CG). At 3 days after
the injection of cells, GFPþ MSCs were present in the (a) parietal
peritoneum, (b) omentum, and (c) diaphragm of CG-injected rats.
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Figure 8 |Mesenchymal stem cells (MSCs) suppressed
glucose-induced upregulation of transforming growth factor-b1
(TGF-b1) and fibronectin expression in human peritoneal
mesothelial cells. Incubation with glucose significantly induced
expressions of (a) TGF-b1 mRNA and (b) fibronectin mRNA compared
with control cells, whereas coculture with human MSCs led to a
significant reduction of TGF-b1 and fibronectin mRNA expression
(n¼ 6). *Po0.01, #Po0.05.
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MSCs in 0.1% fetal bovine serum (FBS) containing
Dulbecco’s modified Eagle’s medium for 2 days, and the
concentrations of HGF and BMP-7 in conditioned medium
were measured by enzyme-linked immunosorbent assays.
HGF concentration in the MSC-CM increased in a time-
dependent manner, whereas it was below the level of
detection in HPMC-CM (Figure 10a). On the other hand,
the concentrations of BMP-7 in MSC-CM and HPMC-CM
were below the level of detection (data not shown). To assess
the effect of HGF on TGF-b signaling, MSC-CM and normal
media were preincubated with or without HGF-neutralizing
antibody (10 mg/ml) for 1 h before its addition to HPMC
cultures. Western blot analysis shows that MSC-CM inhibited
phosphorylation of Smad2 in HPMCs after 30min of
TGF-b1 stimulation and HGF-neutralizing antibody blocked
the inhibitory effect of MSC-CM. These results suggest
the possibility that HGF secreted by MSCs inhibits
TGF-b1-induced EMT responses (Figure 10b).
DISCUSSION
This study has provided the first evidence that MSCs have a
therapeutic potential for the treatment of peritoneal fibrosis
by directly inhibiting TGF-b1 signaling in a paracrine
manner. Intraperitoneal administration of MSCs ameliorated
CG-induced peritoneal fibrosis in rats, as evidenced by a
significant reduction of peritoneal thickening and collagen
deposition, as well as a significant suppression of myofibro-
blast and macrophage accumulation. In addition, MSCs
reduced the functional impairments of the peritoneal
membrane. These results indicate that the beneficial effects
of MSCs on peritoneal damage include reductions in local
pathology, as well as improvements in physiological function.
The injected MSCs were detected on the peritoneal surface
until day 3 in rats following CG-induced peritoneal fibrosis,
but were not seen in rats without peritoneal fibrosis.
These findings suggest that intraperitoneally injected MSCs
migrated to the sites of peritoneal injury and displayed both
immunomodulatory and antifibrotic effects in the absence of
long-term engraftment of the administered cells.
MSCs are known to migrate preferentially to the sites of
inflammation following tissue injury when infused into
animals.33 Although the underlying molecular mechanism
of homing and engraftment by these cells is not yet
fully understood, expression of specific growth factors,
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Figure 9 |Mesenchymal stem cell (MSC)-conditioned media (CM) blocked transforming growth factor-b1 (TGF-b1)-induced epithelial-
to-mesenchymal transition (EMT). Representative photomicrograph shows characteristic cobblestone-like appearances of (a) control
human peritoneal mesothelial cells (HPMCs) and (b) HPMCs incubated with MSC-CM without TGF-b1 stimulation. Fibroblast-like change was
observed following TGF-b1 stimulation for 48 h, but the change was reduced in (d) HPMCs incubated with MSC-CM than in (c) HPMCs
incubated with normal medium. HPMCs were observed by an independent investigator who was blinded to the experimental conditions.
(e) Western blot analysis shows that MSC-CM inhibited phosphorylation of Smad2 in HPMCs after 30min of TGF-b1 stimulation. (f, g) TGF-b1
treatment for 48 h caused increased a-smooth muscle actin (a-SMA) protein expression and decreased zonula occludens-1 (ZO-1) protein
expression. MSC-CM attenuated these TGF-b1-induced EMT responses (n¼ 6). *Po0.01, #Po0.05.
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chemokines, and extracellular matrix receptors on the
surfaces of MSCs may facilitate their trafficking, adhesion,
and infiltration into sites of injury.34,35 In this study,
short-term retention of intraperitoneally administered
GFPþ MSCs into the peritoneal tissues was demonstrated
in rats with CG-induced peritoneal fibrosis, whereas
GFPþ MSCs were not detected in control rats lacking
fibrosis. These findings suggest that the MSCs migrated to the
sites of CG-induced peritoneal damage.
Recently, Sekiguchi et al.36 reported that bone
marrow–derived cells accumulated and were maintained in
the submesothelium for 3 weeks after discontinuation of CG
in a mouse model of CG-induced peritoneal fibrosis. Their
results suggest that bone marrow–derived cells have an
important role in the process of peritoneal repair and
mesothelial remodeling. In this study, retention of bone
marrow–derived MSCs expanded ex vivo was only observed
until day3. However, the anti-inflammatory and antifibrotic
effects in the peritoneum were prolonged until day 14. Such
effects may be independent of transdifferentiation of MSCs
into functional peritoneal mesothelial cells and are more
likely to be due to paracrine activities of MSCs. Previous
in vivo and in vitro studies have suggested that paracrine
mechanisms involving the production of growth factors and
anti-inflammatory cytokines by MSCs are associated with
these properties.37,38 To identify an anti-inflammatory
factor, we performed enzyme-linked immunosorbent assay
to detect anti-inflammatory interleukin-10 in MSC-CM, but
the interleukin-10 concentration of MSC-CM was below the
level of detection (data not shown). In addition, we could
not detect inhibitory effects of MSCs on inflammatory
cytokine signaling such as interleukin-6-induced phospho-
rylation of signal transducer and activator of transcription 3
(data not shown). Although the mechanism of the anti-
inflammatory effect of MSCs in our rat model of peritoneal
fibrosis remains unclear, it has raised the possibility that the
anti-inflammatory paracrine action may affect host
macrophages and not peritoneal mesothelial cells. In fact,
Ne´meth et al.39 reported that MSCs attenuate sepsis through
prostaglandin E2–dependent production of interleukin-10,
which was not directly produced by injected MSCs but by
macrophages.
As part of the immune response to peritoneal injury or
infection in PD patients, various cytokines and growth
factors from migrating macrophages or mesothelial cells were
suggested to contribute to the progression of peritoneal
fibrosis. Among them, TGF-b1 has been identified as the
most potent growth factor inducing EMT in peritoneal
mesothelial cells.7–9,40 Moodley et al.41 reported that
systemically administered human umbilical cord MSCs
suppressed fibrosis of bleomycin-induced lung injury and
inhibited TGF-b1 expression that led to reduction in Smad2
phosphorylation. In this study, we demonstrated that
intraperitoneal injection of MSCs suppressed TGF-b1
expression by migrating macrophages in CG-stimulated rat
peritoneum. Moreover, coculture with MSCs suppressed
glucose-induced gene expression of TGF-b1 by HPMCs
in vitro. Furthermore, we showed that MSC-CM inhibited
TGF-b1-induced phosphorylation of Smad2 and ameliorated
TGF-b1-induced changes in the protein levels of a-SMA and
zonula occludens-1. These results suggest that MSCs acted to
suppress TGF-b1 signaling and TGF-b1-induced EMT
responses in a paracrine manner.
Many investigators have shown that MSCs actively secrete
several essential growth factors.42 HGF and BMP-7 are potent
mediators of antifibrotic cytokines that display therapeutic
potential in preventing tissue fibrosis and disturb TGF-b1
signaling.30–32 A number of studies suggest that HGF and
BMP-7 have a protective role in peritoneal fibrosis.43,44
We showed that the concentration of HGF in MSC-CM
increased in a time-dependent manner, whereas BMP-7 was
undetectable (data not shown). In addition, we demonstrated
that HGF secreted by MSCs is implicated in the inhibition of
the TGF-b1 signaling.
In this study, most of the injected MSCs were presumably
lost because of acute toxicity of CG. However, immunomo-
dulatory and antifibrotic effects of MSCs on peritoneal
fibrosis were observed despite the short retention of
administered cells, and no adverse effects were detected. In
order to improve the outcome, further studies are warranted
to confirm the effect of MSCs in other models of peritoneal
fibrosis and optimal dosage and timing of MSC administra-
tion. In conclusion, our results suggest that MSCs ameliorate
experimental peritoneal fibrosis by suppressing inflammation
and inhibiting TGF-b1 signaling in a paracrine manner.
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Figure 10 |Mesenchymal stem cells (MSCs) secreted hepatocyte
growth factor (HGF) and inhibited transforming growth factor-b1
(TGF-b1) signaling. (a) Human peritoneal mesothelial cells (HPMCs)
and human MSCs were cultured in 0.1% fetal bovine serum (FBS)
containing Dulbecco’s modified Eagle’s medium (DMEM) for 48 h and
HGF concentration in the conditioned media (CM) was measured in
triplicate by enzyme-linked immunosorbent assay (ELISA) and the
mean data were used. HGF concentration in the MSC-CM was
increased in a time-dependent manner, whereas it was below the
detection level in the HPMC-CM. (b) MSC-CM and normal medium
were preincubated with or without HGF-neutralizing antibody
(HGF-Ab; 10 mg/ml) for 1 h before its addition to HPMC cultures.
Western blot analysis shows that MSC-CM inhibited phosphorylation
of Smad2 (pSmad2) in HPMCs after 30min of TGF-b1 stimulation and
HGF-neutralizing antibody blocked the inhibitory effect of MSC-CM
(n¼ 6). *Po0.05.
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MATERIALS AND METHODS
Isolation and culture of MSCs
Bone marrow was collected from rats by flushing the femurs and
cultured as described previously.45 Fourth-passage cells were used
for transplantation. It was confirmed that these cells were MSCs by
promoting their differentiation into osteocytes and adipocytes with
specific differentiation media.45
Injection of MSCs
We used male Fisher 344 rats (CLEA Japan, Tokyo, Japan) at 8 weeks
of age. An injection of 0.1% CG in 15% ethanol dissolved in 2ml of
saline was given intraperitoneally. After 30min, bone marrow MSCs
(1107 cells) suspended in 1ml of phosphate-buffered saline were
injected intraperitoneally or vehicle was injected (n¼ 10 in each
group at each time point). At 7 and 14 days after injection, the rats
were killed and the parietal peritoneum was carefully dissected for
examination. A peritoneal equilibrium test was performed on day
14. Rats were instilled with PD solution (4.25% Dianeal; Baxter
HealthCare, Deerfield, IL) at 100ml/kg body weight before being
killed. After 30min, the peritoneal fluid was removed and blood
samples were obtained by cardiac puncture. The peritoneal permea-
bilities of glucose and blood urea nitrogen were expressed as the
peritoneal absorption of glucose from the dialysate and the
dialysate-to-plasma ratio of blood urea nitrogen.
Next, we used male Sprague–Dawley rats (CLEA Japan) at 8
weeks of age. An injection of 0.1% CG in 15% ethanol dissolved in
2ml of saline was given intraperitoneally, or 15% ethanol in 2ml of
saline was injected as a control (n¼ 5 in each group at each time
point). After 30min, MSCs (1107 cells) obtained from the bone
marrow of GFP-transgenic Sprague–Dawley rats (Japan SLC,
Shizuoka, Japan) and suspended in 1ml of phosphate-buffered
saline were injected intraperitoneally. At 1, 3, 7, and 14 days after
injection, rats were killed and the parietal peritoneum, omentum,
and diaphragm were carefully dissected to immunohistochemically
examine the retention of GFP-positive MSCs.
All of the animal experiments were approved by the institutional
animal care and use committee of Hiroshima University
(Hiroshima, Japan) and were performed in accordance with the
National Institutes of Health Guidelines on the Use of Laboratory
Animals.
Histology and immunohistochemistry
Histology and immunohistochemical staining of 4-mm-thick tissue
sections were performed as described previously.46 The following
primary antibodies were used: mouse monoclonal anti-a-SMA
antibody (Sigma, St Louis, MO); rabbit polyclonal anti-FSP-1
antibody (Abcam, Cambridge, UK); rabbit polyclonal anti-collagen I
antibody (Abcam); rabbit polyclonal anti-collagen III antibody
(Chemicon International, Temecula, CA); mouse monoclonal anti-
rat CD68 antibody (Serotec, Oxford, UK); rabbit polyclonal anti-
TGF-b1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA);
rabbit polyclonal anti-pSmad2 antibody (Chemicon); and rabbit
polyclonal anti-GFP antibody (Clontech, Palo Alto, CA).
The areas of a-SMA, collagen I, and collagen III were assessed in
predetermined fields (200) of the submesothelial compact zone
captured by a digital camera and the area stained was determined
using a Lumina Vision 2.20 (Mitani, Osaka, Japan) in 10 fields. The
numbers of cells positive for FSP-1, CD68, pSmad2 (400), GFP
(100), and CD68/TGF-b1 (double positive, 200) of the
submesothelial compact zone were counted in 10 fields.
Cell culture
Specimens of human omentum were obtained from patients
undergoing elective abdominal surgery without peritonitis or
peritoneal carcinosis. The HPMCs were isolated from human
omentum as described previously.47 Chemicals and plastic tissue
culture dishes were as described in our earlier studies,48 and cells
from the second to third passages were used. Harvesting of the
omentum was permitted by the Medical Ethics Committee of
Hiroshima Graduate School of Biomedical Science, and informed
consent was obtained from each patient. We performed individual
experiments using HPMCs from different isolates at least three
times. Human bone marrow MSCs were purchased from Bio
Whittaker (Walkersville, MD).
HPMCs (1105 cells/well) were seeded into six-well plates and
grown to subconfluence. The culture medium was then replaced
with Dulbecco’s modified Eagle’s medium plus 2% FBS alone
(control) or 2% FBS plus 4% D-glucose for 12 h. To test the effect of
coculture of glucose-stimulated HPMCs with human MSCs while
avoiding direct cell contact, human MSCs (1105 cells/well) were
grown on the bottom of upper well inserts (0.4 mm pore size; Becton
Dickinson Labware, Franklin Lakes, NJ). Inserts with cultured MSCs
or medium alone were then dipped into the basal plate of cultured
glucose-stimulated HPMCs for 24 h. Expression of TGF-b1 and
fibronectin mRNAs by HPMCs was assessed by reverse
transcription–PCR.
MSC-CM was prepared by exposing B80% confluent human
MSC cultures to 0.1% FBS containing Dulbecco’s modified Eagle’s
medium for 2 days. HPMCs (1105 cells/well) were seeded into
six-well plates and grown until subconfluence. The culture medium
was then replaced with Dulbecco’s modified Eagle’s medium plus
0.1% FBS alone or MSC-CM for 12 h and HPMCs were incubated in
the absence or presence of 2.5 ng/ml recombinant human TGF-b1
(R&D Systems, Minneapolis, MN). Antibody neutralization of
MSC-CM was performed with 10 mg/ml anti-human HGF antibody
(AF-294-NA; R&D Systems) at 37 1C for 1 h before its addition
to HPMC cultures. Whole-cell lysates were prepared and subjected
to western blot analysis.
RNA extraction and quantitative real-time reverse
transcription–PCR
RNA extraction and reverse transcription–PCR were performed as
previously described.49 Specific oligonucleotide primers and probes
for TGF-b1 (assay ID: Hs99999918_m1), fibronectin (assay ID:
Hs00365058_m1), and 18S rRNA (endogenous control) were
obtained as TaqMan Gene Expression Assays (Applied Biosystems,
Foster City, CA). The mRNA levels were normalized for the level of
18S rRNA.
Western blot analysis and enzyme-linked immunosorbent
assay
Sample collection and immunoblotting were performed as
previously described.50 Primary antibodies used in this study were
anti-phosphorylated Smad2 (Cell Signaling Technology, Beverley,
CA), anti-Smad2 (Cell Signaling), mouse monoclonal anti-a-SMA
antibody (Sigma), rabbit polyclonal anti-zonula occludens-1
(Zymed, San Francisco, CA), and mouse monoclonal
anti-a-tubulin antibody (Santa Cruz Biotechnology). Secondary
antibodies used in this study were horseradish peroxidase–conju-
gated goat anti-rabbit immunoglobulin G antibody (Dako, Glostr-
up, Denmark) or goat anti-mouse immunoglobulin G antibody
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(Dako). Signals were detected using the SuperSignal West Dura
system (Thermo Fisher, Rockford, IL). The intensity of each band
was determined using ImageJ software (version 1.44p; National
Institutes of Health, Bethesda, MD). The enzyme-linked immuno-
sorbent assay analyses for HGF and BMP-7 (R&D Systems) were
performed following the manufacturer’s instructions. The results
were normalized to the total protein content.
Statistical analysis
Results are expressed as the mean±s.e. Statistical analysis was
performed using analysis of variance followed by Tukey’s post hoc
test, and Po0.05 was considered to be statistically significant.
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